MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Prevention and treatment of pancreatic cancer

Back to pancreas Blogs list Cancer blog  


Subscribe To Pancreas RSS Feed  RSS content feed What is RSS feed?

Prevention and treatment of pancreatic cancer




A number of gastrointestinal tumors, including pancreas cancer, have been shown to overexpress the EGFR. The overexpression of EGFR correlates with rapidly progressive disease and poor prognosis. Targeting EGFR pathway as a potential therapeutic strategy for pancreas cancer has been developed. Erlotinib is a small molecule tyrosine kinase inhibitor that efficiently blocks EGFR. Preliminary results of phase III trial in pancreas cancer revealed an improvement in survival with the addition of erlotinib. Treatment with anti-EGFR agents is used as a potential therapeutic strategy for pancreas cancer, but the mechanisms are still not precisely understood.



Prevention and treatment of pancreatic cancer

This article was published on September 21, 2008 in the World Journal of Gastroenterology The research team from Department of Gastroenterology, Affiliated First People's Hospital, Shanghai Jiao Tong University, China studied the effects of erlotinib on six different pancreas cancer cell lines. How erlotinib exhibits its antineoplastic activity in vivo needs to be further elucidated.

In this study authors revealed the efficacy of erlotinib, as a single agent, on pancreas cancer cells growth in vitro, and in vivo study using a nude mice xenograft model and the mechanisms involved were also explored. Erlotinib repressed BxPC-3 cell growth in a dose-dependent manner, triggered G1 arrest and induced cell apoptosis,and suppressed capillary formation of endothelium in vitro. In vivo, erlotinib treated mice demonstrated a reduced tumor volume and weight as compared with control. The relationship between EGFR and angiogenesis has also been investigated using tube formation assay in vitro and immunohistochemical analysis of tumor-associated blood vessels in vivo. These findings provide evidence for the inhibitive activity of erlotinib in pancreas cancer cells. Inhibition of EGFR may be a promising adjuvant in chemotherapeutic strategy in the therapy of the dismal disease. The results also demonstrate that EGFR signaling pathway is an important target in pancreas cancer.


Posted by: Sue    Source




Did you know?
A number of gastrointestinal tumors, including pancreas cancer, have been shown to overexpress the EGFR. The overexpression of EGFR correlates with rapidly progressive disease and poor prognosis. Targeting EGFR pathway as a potential therapeutic strategy for pancreas cancer has been developed. Erlotinib is a small molecule tyrosine kinase inhibitor that efficiently blocks EGFR. Preliminary results of phase III trial in pancreas cancer revealed an improvement in survival with the addition of erlotinib. Treatment with anti-EGFR agents is used as a potential therapeutic strategy for pancreas cancer, but the mechanisms are still not precisely understood.

Medicineworld.org: Prevention and treatment of pancreatic cancer

Advances in pancreatic cancer treatment| Detailed information on pancreatic cancer| Pancreas cancer main| Major topics in pancreatic cancer| Overview of pancreatic cancer| Pancreatic cancer resources| More resources for pancreatic cancer| Resources 3 for pancreatic cancer| Resources4 for pancreatic cancer| Resources5 for pancreatic cancer| Resources6 for pancreatic cancer| Resources7 for pancreatic cancer| Resources8 for pancreatic cancer|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.